Search results
Results from the WOW.Com Content Network
To improve clinical outcomes very early treatment with surfactant is necessary. [13] However, only about half of infants with a gestational age (GA) below 30 weeks need surfactant treatment [ 14 ] [ 15 ] and prophylactic surfactant treatment increases the combined mortality and incidence of Bronchopulmonary Dysplasia (BPD) contrary to selective ...
Conditions adult respiratory distress syndrome or Hyaline Membrane Disease are also sometimes treated with exogenously derived surfactant. One of the more common uses of surfactant therapy is to treat alveolar surfactant deficiency in premature newborns. Most commonly, treatment is composed of multiple doses of 100 mg/kg of exogenous surfactant ...
Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies. [1] Prevention is generally done in babies born at a gestational age of less than 32 weeks. [1] It is given by the endotracheal tube. [1] Onset of effects is rapid. [2] A number of doses may be needed. [2]
In 1989, at Holbaek Hospital, Verder was the first physician to successfully combine nasal CPAP and surfactant to treat an infant with severe RDS (28 weeks). This unique method was later named INSURE by Mats Blennow et al. [ 5 ] The full method was first published in 1992 along with the first documentation of infants treated with surfactant via ...
These lamellar bodies are secreted by exocytosis into the alveolar lining fluid, where the surfactant forms a meshwork of tubular myelin [17] [18] Full term infants are estimated to have an alveolar storage pool of approximately 100 mg/kg of surfactant, while preterm infants have an estimated 4–5 mg/kg at birth. [19]
Transient tachypnea of the newborn occurs in approximately 1 in 100 preterm infants and 3.6–5.7 per 1000 term infants. It is most common in infants born by caesarian section without a trial of labor after 35 weeks of gestation. Male infants and infants with an umbilical cord prolapse or perinatal asphyxia are at higher risk.
Infant respiratory distress syndrome is the leading cause of death in preterm infants, [29] and the main treatments are CPAP, in addition to administering pulmonary surfactant and stabilizing the blood sugar, blood salts, and blood pressure.
The first treatment given to some newborns with RDS was surfactant phospholipids, specifically DPPC, by means of an aerosol (Robillard, 1964). [full citation needed] This treatment proved ineffective because administration of DPPC alone did not provide any beneficial effects. Subsequently, studies were carried out to find more effective drugs ...